Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DP303c vs Trastuzumab Emtansine in HER2-positive Advanced Breast Cancer
NCT06313086Phase 3Recruiting
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- Mar 2024
- Primary completion
- Dec 2025
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 3 trial of DP303c in HER2-positive breast cancer, sponsored by CSPC ZhongQi Pharmaceutical Technology. Started Mar 2024; status: recruiting.
02
Drugs
DP303c
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT06313086.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06313086.